Taysha Gene Therapies (TSHA) Enterprise Value (2020 - 2026)

Taysha Gene Therapies has reported Enterprise Value for 7 years, with the latest figure at -$277.0 million in Q1 2026.

• Quarterly Enterprise Value fell 136.71% year-over-year to -$277.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$277.0 million (down 136.71% YoY) and the FY2025 annual result came in at -$320.2 million, down 129.57% from the prior year.
• Enterprise Value advanced to -$277.0 million in Q1 2026 per TSHA's latest filing, from -$320.2 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$36.9 million in Q3 2022 and troughed at -$320.2 million in Q4 2025.
• A 5-year average of -$158.8 million and a median of -$141.9 million in 2023 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value jumped 80.7% in 2022, then sank 344.68% in 2023.
• Over 5 years, Enterprise Value stood at -$36.9 million in 2022, then tumbled by 290.84% to -$144.4 million in 2023, then grew by 3.4% to -$139.5 million in 2024, then tumbled by 129.57% to -$320.2 million in 2025, then climbed by 13.48% to -$277.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$277.0 million, -$320.2 million, and -$297.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.